Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Harvard Business School
Mallinckrodt
Colorcon
Merck

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Litigation Details for In Re:Metoprolol Succinate Patent Litigation (E.D. Mo. )

See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in In Re:Metoprolol Succinate Patent Litigation
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for In Re:Metoprolol Succinate Patent Litigation (E.D. Mo. )

Date Filed Document No. Description Snippet Link To Document
2006-01-17 363 the ‘318 patent) and United States Patent 4,957,745 (the ‘745 patent); and that the ‘154 patent is invalid…. These patents are United States Patent 5,001,161 (the ‘161 patent) and United States Patent 5,081,154… ‘154 patents are invalid for double patenting over earlier issued patents United States Patent 4,780,318… ‘161 patent and’154 patent are invalid based on double patenting of claim 8 of the ‘318 patent. Defendants…‘161 patent and the ‘154 patent are invalid for double patenting over claim 8 of the ‘318 patent. Because External link to document
2006-02-10 367 Plaintiff`s’ Claim of Infringement of U.S. Patent 4,957,745 against Defendant KV Pharmaceutical Comp_any…Company for in&ingement of Plaintiffs’ U.S. Patent 4,957,745 shall be and hereby is DISMISSED WITH PREJUDICE… of noninfringement and invalidity of U.S. Patent 4,957,745 shall be and hereby are dismissed as moot.…judgment that U.S. Patent 5 ,001 ,161 is unenforceable for inequitable conduct, and U.S. Patent 5,001,161 shall…judgment that U.S. Patent 5,081,154 is unenforceable for inequitable conduct, and U.S. Patent 5 ,081,1 54 shall External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
McKinsey
Boehringer Ingelheim
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.